Cibus Inc (NASDAQ: CBUS) is an agricultural biotechnology company that develops gene-edited crop traits using its proprietary Rapid Trait Development System (RTDS) technology platform. Revenue is recognized from research collaboration agreements, technology licenses, product development activities, and milestone payments under collaboration arrangements. The company is pre-commercial and has incurred losses since inception, reporting a net loss of $132.2 million and cash used in operating activities of $50.6 million for the year ended December 31, 2025. As of December 31, 2025, Cibus held $9.9 million in cash and equivalents against $16.9 million in current liabilities. The company underwent a restructuring in late 2024, reducing its workforce and closing its San Diego trait development facility in August 2025, while concentrating resources on weed management traits for rice and advancing traits including Podshatter Reduction (PSR) in winter oilseed rape in the United Kingdom and Sclerotinia resistance in canola and soybean.

Revenue model

Cibus earns revenue through research collaboration agreements (non-refundable R&D payments, cost reimbursements, and milestone payments), technology licenses, and product development services for partners. No commercial product sales revenue is disclosed as material in the FY2025 filing.

Products and services

Key trait programs include: Podshatter Reduction (PSR) in winter oilseed rape (WOSR), with regulatory filings submitted in the United Kingdom in January 2026; weed management traits for rice, identified as the primary commercial focus as of mid-2025; Sclerotinia resistance in canola and soybean; and Light Leaf Spot resistance in oilseed rape, developed under the DEFRA-funded LLS-ERASED consortium in the United Kingdom. The underlying technology platform is RTDS (Rapid Trait Development System), described as gene editing without foreign DNA insertion.

Customers and end markets

End markets are seed companies, agricultural growers, and food producers. Customers engage Cibus through collaboration and licensing agreements. No individual customer concentration percentages are disclosed in the excerpts. Key crops addressed include canola, oilseed rape, rice, and soybean.

Value-chain role

Cibus operates as a trait development and licensing company, sitting upstream of seed companies and growers. It develops gene-edited plant traits and licenses or partners those traits to agricultural companies rather than selling seed or crop inputs directly.

Geographic exposure

Primary development and regulatory activity is in the United States, United Kingdom (PSR trait filings submitted January 2026 under the Precision Bred Organisms framework effective November 13, 2025), and the European Union. Regulatory frameworks noted in India, Japan, Thailand, and the Philippines indicate awareness of those markets, though no commercial operations there are confirmed in the excerpts.

Source: SEC 10-K, filed 2026-03-17

Industry: Agricultural Chemicals Peers: Benitec Biopharma Inc TuHURA Biosciences Inc Sonnet BioTherapeutics Holdings, Inc. CohBar, Inc. Ensysce Biosciences Inc Exicure Inc Xenetic Biosciences Inc Phio Pharmaceuticals Corp Unicycive Therapeutics Inc